VEGFA and glioblastoma: Selection for a more invasive phenotype is supported by preclinical studies that revealed increased ‘satellites’ of infiltrative tumour that co-opt normal host vessels in orthotopic GBM xenografts treated with a VEGF monoclonal antibody (Rubenstein et al, 2000).